Daniel R. Chevallard
CIK 1706176 · Chief Financial Officer · last filed 2026-03-30
Daniel R. Chevallard is a Chief Financial Officer who has filed 31 SEC Form 4 insider transactions across 3 companies since 2017. The most recent filing shows the insider bought $64.3K of LENZ on Mar 30, 2026. Across all open-market trades the lifetime net is +$94.1K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $87.2K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$87.2K
3
31
$94.1K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LENZ | Chief Financial Officer | 12,886 | $6.77 | $87.2K | $164.3K | 5 | 2026-03-30 |
| Viracta Therapeutics, Inc. (VIRX) Delisted | CFO and COO | 102,306 | $0.01 | $1.0K | -$99.4K | 16 | 2024-03-13 |
| Regulus Therapeutics Inc. (RGLS) Delisted | Chief Financial Officer | 77,870 | $8.16 | $635.4K | $29.2K | 9 | 2019-07-02 |
Recent Filings
31 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-30 | LENZ | Buy (P) | +7,500 | $64.3K | EDGAR |
| 2026-01-06 | LENZ | Grant (A) | — | $0 | EDGAR |
| 2025-11-07 | LENZ | Buy (P) | +2,198 | $50.0K | EDGAR |
| 2025-01-13 | LENZ | Grant (A) | — | $0 | EDGAR |
| 2024-05-15 | LENZ | Buy (P) | +3,188 | $50.0K | EDGAR |
| 2024-03-25 | — | Grant (A) | — | $0 | |
| 2024-03-13 | Viracta Therapeutics, Inc. (VIRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-02-27 | Viracta Therapeutics, Inc. (VIRX) Delisted | Mixed | +3,484 | -$2.5K | EDGAR |
| 2023-11-28 | Viracta Therapeutics, Inc. (VIRX) Delisted | Mixed | +3,169 | -$1.9K | EDGAR |
| 2023-08-29 | Viracta Therapeutics, Inc. (VIRX) Delisted | Mixed | +3,376 | -$5.1K | EDGAR |